Abstract Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. Emerging data suggest that these rare tumors exhibit immunogenicity, potentially benefiting from intensified immunotherapy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jaume Capdevila
Constel·lació d'Ànimes
El ninotaire Jaume Capdevila (KAP) ha assistit a l'homenatge que el musical Ànima ha dedicat a les il·lustradores del país coincidint amb el Dia Internacional del Disseny. Foto de família amb l'equip d'Ànima i les il·lustradores convidades el 29 d'abril Comparteix la notícia Ànima és un musical que es pot veure fins al 24 de maig al Teatre Tívoli.
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial
|
By Jaume Capdevila, Jorge Hernando, María Plana Serrahima, Beatriz Castelo, Cristina Álvarez-Escola, Alberto Carmona-Bayonas, Inmaculada Navarro, Lara Romero Iglesias, Mateo Bover, Alejandro Garcia-Alvarez, Javier Lavernia, Sofia Ruiz, Sofía Ruiz, Neus Basté, Enrique Sanz-Garcia, Gloria Marquina, Paolo Nuciforo, Enrique Grande, Teresa Alonso-Gordoa, Javier Molina-Cerillo, Miren Taberna Sanz, Ricardo Yayá Tur, Isabel Lorenzo-Lorenzo, Alfredo Sanchez-Hernandez, Belén Elguero
|
Nature
Verified
Abstract Single-agent PD-1 blockade demonstrated promising efficacy in advanced thyroid cancer. The phase II, single-arm, multi-cohort GETNE-DUTHY trial (clinicaltrials.gov NCT03753919, EudraCT 2018-001066-42) aimed to determine whether dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelimumab can improve the clinical outcomes in advanced thyroid cancer.
Frontiers | Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor
Abstract ALK rearrangements are rare but actionable oncogenic drivers in thyroid cancer, particularly in aggressive histologies such as poorly differentiated thyroid carcinoma (PDTC), and evidence supporting sequential ALK inhibition in this setting is scarce. We report a 19-year-old male with ALK-rearranged, radioiodine-refractory PDTC who started systemic therapy with ceritinib, achieving a complete metabolic response.
Densities for Hausdorff measure and rectifiability. Besicovitch’s 1/2-conjecture
Ayuda Buscar en la ayuda Buscar en la ayuda Densities for Hausdorff measure and rectifiability. Besicovitch’s 1/2-conjecture [1] Universitat Autònoma de Barcelona Localización: Reports@SCM: an electronic journal of the Societat Catalana de Matemàtiques, ISSN-e 2385-4227, Vol. 10, Nº. 1, 2025, págs. 77-78 Idioma: inglés Títulos paralelos: Densitats per la mesura de Hausdorff i rectificabilitat.
Así se dibujó el póster de la plantilla del Barça para ‘La Vanguardia’
Cómo se hizo Es lunes. El Barça de Flick acaba de ganar su cuarto clásico al Real Madrid. El título de Liga está a punto de engrosar el museo azulgrana. Yo estaba en la biblioteca con mi hija, cuando el móvil empieza a vibrar en mi bolsillo. Salgo al pasillo para contestar sin molestar al meditabundo enjambre de lectores concentrados en sus cosas.
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer
|
By Adria Marcos Morales, Marta Ligero, David Leiva, Cristina Viaplana, Joaquin Mateo, Jorge Hernando, Alejandro Garcia-Alvarez, Francesc Salvà, Jaume Capdevila, Elena Elez, Rodrigo Dienstmann, Elena Garralda, Raquel Perez-Lopez, Maria Balaguer-Montero, Christina Zatse, Luz M. Atlagich, Nikolaos Staikoglou, Camilo Monreal
|
Cell Reports Medicine
Verified
ArticleOnline now102032Open access 1Radiomics Group, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain 2Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, TUD Dresden University of Technology, 01307 Dresden, Germany 3Bellvitge University Hospital, 08907 Barcelona, Spain 4Oncocentro Apys, Viña Del Mar 2520598, Chile 5Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain 6Department of Medical...
Garabatos del 29/X/2024
{"allowComment":"allowed","articleId":"article-10056434","url":"https:\/\/www.lavanguardia.com\/opinion\/20241029\/10056434\/garabatos-29-x-2024.html","livefyre-url":"article-10056434"}
Garabatos del 28/X/2024
{"allowComment":"allowed","articleId":"article-10050665","url":"https:\/\/www.lavanguardia.com\/opinion\/20241028\/10050665\/garabatos-28-x-2024.html","livefyre-url":"article-10050665"}
Garabatos del 22/X/2024
{"allowComment":"allowed","articleId":"article-10038589","url":"https:\/\/www.lavanguardia.com\/opinion\/20241022\/10038589\/garabatos-22-x-2024.html","livefyre-url":"article-10038589"}
Garabatos del 21/X/2024
{"allowComment":"allowed","articleId":"article-10036959","url":"https:\/\/admin.lavanguardia.com\/view\/opinion\/20241021\/10036959\/garabatos-21-x-2024.html","livefyre-url":"article-10036959"}
Garabatos del 15/X/2024
{"allowComment":"allowed","articleId":"article-10019384","url":"https:\/\/www.lavanguardia.com\/opinion\/20241015\/10019384\/garabatos-15-x-2024.html","livefyre-url":"article-10019384"}
Garabatos del 14/X/2024
{"allowComment":"allowed","articleId":"article-10021781","url":"https:\/\/www.lavanguardia.com\/opinion\/20241014\/10021781\/garabatos-14-x-2024.html","livefyre-url":"article-10021781"}
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913) | Nature Communications
Abstract The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is a single-arm, phase II trial that recruited chemotherapy-naive, unresectable advanced or metastatic G3 NENs of gastroenteropancreatic (GEP) or unknown origin.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
Keywords: vandetanib; multikinase inhibitor; differentiated thyroid cancer; progression-free survival; radioiodine refractory Introduction Differentiated thyroid cancer (DTC), including papillary, follicular, oncocytic carcinoma, and poorly differentiated cancers, arises from aberrant follicular cells of the thyroid and accounts for >90% of all thyroid malignancies (Sherman 2003, Haugen et al. 2016).
Literatura pels ulls: el pes de la tradició literària en les primeres historietes catalanes
IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study
Abstract Background The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE-158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers.
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era
Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424 Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13: 184-199 Lloyd R.V. Osamura R.Y. Klöppel G. Rosai J. WHO classification of tumours of endocrine organs. 4th Edition:. WHO Press, 2017 Ganly I. Makarov V. Deraje S. Dong Y. Reznik E. Seshan V. et al.
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) | Journal of Clinical Oncology
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
Highlights • Neuroendocrine neoplasm (NEN) management requires a multidisciplinary approach. • Evidence is lacking to guide adjustments to standard-of-care during the COVID-19 era. • Multiple countries are now experiencing diverse trajectories of the COVID-19 pandemic. • NEN centres worldwide have shared experiences to preserve high standards of care. • We suggest potential strategies to reduce risk and aid multidisciplinary approach.
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, MD, PhD1; Lori J. Wirth, MD2; Thomas Ernst, MD3; Santiago Ponce Aix, MD4; Chia-Chi Lin, MD, PhD5; Rodryg Ramlau, MD, PhD6; Marcus O. Butler, MD7; Jean-Pierre Delord, MD, PhD8; Hans Gelderblom, MD, PhD9; Paolo A. Ascierto, MD10; Angelica Fasolo, MD11; Dagmar Führer, MD, PhD12; Marie Luise Hütter-Krönke, MD13; Patrick M. Forde, MBBCh14; Anna Wrona, MD, PhD15; Armando Santoro, MD16; Peter M.
Meta‐Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors
Advertisement Advertisement Jaume Capdevila (jacapdevila{at}vhebron.net)*,a, Jorge Hernandoa, Santiago Perez‐Hoyosb, Alejandro Roman‐Gonzalezc and Enrique Granded a Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain b Biostatistics and Bioinformatics Unit, Vall d'Hebron Research Institute, Barcelona, Spain c Department of Endocrinology, San Vicente Fundacion University Hospital‐Antioquia University, Medellin, Colombia d...
Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer
Publication HistoryPublished online: July 02, 2018Accepted: June 29, 2018; Received in revised form: June 28, 2018; Received: December 18, 2017;
Centenari del Cu-Cut!
Catalunya ha estat un país amb una llarga tradició periodística. I dins del nostre periodisme, les publicacions humorístiques i satíriques hi han tingut, històricament, un paper important. Durant el darrer terç del segle XIX, La Campana de Gràcia es convertí en la primera publicació catalana de gran abast i va obrir el camí a una llarga tradició de títols destacats que, servint-se de l’humor i la sàtira, provaren d’incidir en la vida social i política del seu temps.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jaume
Contact Jaume, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack